- Advertisement -
Perth-based Emyria (ASX: EMD), an ASX-listed biotech that specialises in clinical services and treatments for mental health and neurological conditions, has undertaken a leadership change ahead of anticipated growth in 2025 that has partly been aided by a new administration in the US.
CEO Dr…